Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 4
Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Boston and Winston-Salem, United StatesSee the 2 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 78 people, planned
- Started
- Nov 2026
- Expected to end
- 7 Oct 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Angiotensin II
- Norepinephrine
- Record updated
- 24 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate >2mmol/L 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg/kg/min and ≤0.5 mcg/kg/min, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival
Who cannot take part
- Patients for whom urgent surgery is anticipated
- Bone marrow transplant within the past 30 days
- history of liver cirrhosis with Child-Pugh score ≥6
- Leukocyte count <1,000 cells/μL
- Absolute monocyte count <200 cells/μL
- Age <18 years
- Prisoners
- Pregnant women
- Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support
- transfer from outside ICU
Where in United States
- Massachusetts General Hospital-HarvardBoston, United StatesContact: Michael R Filbin, MD, MSNot yet recruiting
- Atrium Health Wake Forest BaptistWinston-Salem, United StatesContact: Ashish Khanna, MDNot yet recruiting
About the trial
What the trial wants to find out
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
The 2 groups in the trial
- Angiotensin IITreatment being tested
Continuous infusion of Angiotensin II for up to 48 hours
- NorepinephrineExisting treatment, for comparison
Continuous infusion of Norepinephrine for up to 48 hours
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) Grant Submission- Dysfunctional Renin-Angiotensin System in Septic Shock
- Record updated
- 24 September 2026